Clinical trials: Nonsmall Cell Lung Cancer Stage III
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC]…
- Trial name
- NCT03519971
- Testing
- Durvalumab, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel
- Where
- 86 sites in Brazil, Czechia and 12 more
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic
A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
The main purpose for this study is to answer the following research questions: Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting? Will the participant be…
- Conditions
- Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB
- Trial name
- NCT01473563
- Testing
- Pemetrexed
- Where
- 9 sites in Sweden, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer (Stage III)
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
This study is a phase 2 open-label, single-center clinical study to evaluate the efficacy and safety SKB264 in combination with toripalimab in patients with unresectable stage III non-small cell lung cancer
- Trial name
- NCT06706219
- Testing
- Sacituzumab tirumotecan plus toripalimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01208064
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
- Where
- 22 sites in Belgium, Egypt and 6 more
- Volunteers
- 102 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Small Cell Lung Cancer
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
OBSTINATE is an observational, national, prospective, multicentric study on Quality of life in patients with unresecable stade III non-small cell lung cancers.
- Trial name
- OBSTINATE (NCT05049044)
- Testing
- Quality of Life Questionnaire-Core 30 (QLQ-C30)
- Where
- 34 sites in France
- Volunteers
- 413 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05340309
- Testing
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Southern California
Stage IV Non-small Cell Lung Cancer
IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
The objective of this trial is to improve the duration of control disease for PS 0-1 patients who are not progressing on first-line cisplatin-gemcitabine chemotherapy.
- Trial name
- NCT00300586
- Testing
- observation, gemcitabine, erlotinib
- Where
- France
- Volunteers
- 842 people
- Sponsor
- Hospices Civils de Lyon
Lung Cancer
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00589056
- Testing
- cisplatin, etoposide, nelfinavir mesylate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy
Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC
Objective: To evaluate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) during definitive concurrent chemoradiotherapy (cCRT) in patients with…
- Conditions
- Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status
- Trial name
- NCT06958614
- Testing
- Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor
- Where
- China
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Depression
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00387348
- Testing
- escitalopram oxalate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer, Nonsmall Cell, Lung Cancer Stage I
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
The goal of this clinical trial is to evaluate the preliminary affects of "Breathe Easier," an evidence-based multi-level mindfulness intervention (i.e., progressive web application) for survivors of lung cancer.
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer Stage III
- Trial name
- Breathe Easier (NCT06060964)
- Testing
- Breathe Easier Progressive Web Application
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of South Carolina
Stage IV, NSCLC, Lung Neoplasms
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
This is a randomized phase III trial that will randomize elderly patients(70 years of age and older) who are not considered eligible for standard doublet or triplet regimens.
- Conditions
- Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic
- Trial name
- EPIC (NCT03402048)
- Testing
- Carboplatin, Gemcitabine, Pemetrexed
- Where
- 28 sites in Italy
- Volunteers
- 567 people
- Sponsor
- University of Turin, Italy
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared…
- Trial name
- IMpower150 (NCT02366143)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 1,202 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography, using the drug fluorine F18-EF5 to find oxygen and fludeoxyglucose F18 to find sugar in tumor cells may help in planning treatment for patients with…
- Trial name
- NCT01017133
- Testing
- fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004199
- Testing
- cisplatin, gemcitabine hydrochloride, prinomastat
- Where
- United States
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV…
- Trial name
- NCT01828099
- Testing
- Ceritinib, Pemetrexed, Cisplatin
- Where
- 167 sites in Argentina, Australia and 27 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals